Articles from Actinogen Medical

Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
XanaMIA trial fully enrolled with final results expected in November 2026
By Actinogen Medical · Via GlobeNewswire · February 2, 2026
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
On track for interim analysis in late January 2026 and topline final results November 2026
By Actinogen Medical · Via GlobeNewswire · December 18, 2025
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025
By Actinogen Medical · Via GlobeNewswire · September 15, 2025
Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
Phase 2b/3 Alzheimer’s trial enrolment expected to reach 100 this quarter, triggering an interim analysis 6 months later
By Actinogen Medical · Via GlobeNewswire · April 30, 2025